Cellectar Q1 net loss $0.74/share; cash $40M; WM study data in June

Cellectar Biosciences, Inc.

2024-Q1 EPS reported -$0.74

Net loss of $21.6M ($0.74/share) in Q1 2024 vs $8.6M ($0.76/share) in Q1 2023; cash $40.0M.
CLOVER WaM pivotal study met primary endpoint: major response rate 61%; full data in June; NDA submission on track for H2 2024.
Cash $40.0M as of March 31, 2024, expected to fund operations into Q4 2024; net cash used in operations ~$13M in Q1.
Phase 1b pediatric high-grade glioma study enrolled first patient; data expected H2 2024.
Preclinical data for alpha-emitting CLR 121225 in pancreatic cancer; phase 1 planned by Q1 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cellectar Biosciences, Inc. reported the quarter ended March 31, 2024 results: net income The net loss attributable to common stockholders for the three months ended March 31, 2024, was ($21.6) million, or $(0., EPS $(0.74) per share.

Period: the quarter ended March 31, 2024
Net income: The net loss attributable to common stockholders for the three months ended March 31, 2024, was ($21.6) million, or $(0.
EPS: $(0.74) per share
Result: reported results

Exact text from the filing

Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Cellectar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-060865

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.